Dover-based biotech firm The Cat Health Company has raised $1.2 million to advance its work in longevity therapeutics, aiming to help cats live longer and healthier lives, as Vestbee was told.
- Established in 2024 by Alex Voda and Alex Bacita, The Cat Health Company develops longevity therapeutics for cats, targeting the biological processes of aging rather than only treating symptoms of disease.
- The firm uses computational modeling, machine learning algorithms, and in silico prediction to design and optimize medicines that address the molecular mechanisms of aging. These programs are then validated in the lab and advanced into clinical stages.
- By focusing on delaying the onset of age-related conditions such as arthritis, cognitive decline, and mobility loss, the company aims to extend the healthy lifespan of companion cats while also generating insights that could be applied to broader veterinary and potentially human medicine.
- Last year, the firm secured €500,000 in funding from Early Game Ventures and several business angels to advance its research into promising therapies and support the development and introduction of new treatments.
Details of the deal
- The round was led by Portfolia’s Active Aging & Longevity Fund II, with participation from 100 Plus Capital,Early Game Ventures, and Alex Zhavoronkov.
- With the fresh capital raised, the firm aims to accelerate its clinical research, advance new therapeutic programs, and expand its team to bring life-extending treatments for cats to market more quickly.
with this funding, we will accelerate our clinical research, develop new programs, and also expand our team to make sure we can bring these life-extending therapies to the cats who need them most, faster," claims Alex Bacita, COO of The Cat Health Company.
